In re Katz

687 F.2d 450, 215 U.S.P.Q. (BNA) 14, 1982 CCPA LEXIS 110
CourtCourt of Customs and Patent Appeals
DecidedAugust 27, 1982
DocketAppeal No. 82-521
StatusPublished
Cited by32 cases

This text of 687 F.2d 450 (In re Katz) is published on Counsel Stack Legal Research, covering Court of Customs and Patent Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Katz, 687 F.2d 450, 215 U.S.P.Q. (BNA) 14, 1982 CCPA LEXIS 110 (ccpa 1982).

Opinions

NIES, Judge.

This appeal is from the decision of the Patent and Trademark Office (PTO) Board of Appeals (board) sustaining rejection of claims 1, 5,17, and 18, all remaining claims in application Serial No. 937,574 for “Induction of Immunological Tolerance.” The subject application is a divisional application of application Serial No. 764,586, filed February 3, 1977, and is entitled to that filing date. The claims were rejected because of a description of the subject matter of the invention in a publication dated June 1976, which appellant, however, asserts is a description of his own work. The board was unpersuaded by appellant’s declarations to that effect and sustained the rejection. We reverse.

Background

In June, 1976, eight months before appellant’s effective filing date, an article coauthored by Nicholas Chiorazzi, Zelig Eshhar and appellant was published in the Proceedings of the National Academy of Science, U.S.A., Vol. 73, No. 6, pp. 2091-95. There is no dispute that the article (Chiorazzi et al.) fully describes the claimed invention.

Along with his divisional application, appellant filed a declaration in which he declared that:

He is the sole inventor of the subject matter described and claimed in the United States Patent Application Serial No. 764,586, filed February 3, 1977, entitled, INDUCTION OF IMMUNOLOGICAL TOLERANCE, which subject matter is disclosed and claimed in part in the divisional application with which this declaration is submitted.
He is co-author of a report in the proceedings of the National Academy of Science, U.S.A., Volume 73, No. 6, Pages 2091-2095, June, 1976, communicated to the National Academy of Science by Albert H. Coons, a member of said Academy, on March 8, 1976, that he is the sole inventor of the subject matter which is disclosed in said publication in the proceedings of the National Academy of Science and disclosed and claimed in the application submitted herewith. [Emphasis ours.]
The other authors of the publication, Nicholas Chiorazzi and Zelig Eshhar were students working under the direction and supervision of the inventor, Dr. David H. Katz, and while co-authoring the publication, are not co-inventors of the subject matter described therein.

The Examiner’s Rejections

In his first Official Action, the examiner stated:

Claims 1, 5, 17 and 18 are rejected under 35 USC 102(g) as anticipated by Chiorazzi et al. ... Applicant’s declaration ... is entirely ineffective in overcoming the rejection of this nature and is considered to be nothing more than the self-serving statement.

In his Final Official Action, the examiner adhered to the § 102(g) rejection adding:

[T]here is no evidence of record which makes it clear that appellant is the sole [453]*453inventor of the chimed invention .... Where a reference is from a collection of authors, it must be assumed that all authors contributed equally even though it is recognized that sometimes individuals involved only with assay and testing features of the invention and . .. not involved in the conceptial [sic] aspect of the research are included as an author to a particular reference. There is not sufficient evidence of record to show that applicant is the sole inventor of the claimed invention. * * * * * *
... The publication date as well as communication date of the reference, both dates being prior to applicant’s filing date, [are] clear evidence to [sic] prior invention. [Emphasis in original].

To overcome the rejection, the examiner required that appellant either (1) amend his application to include the other authors as coinventors, or (2) file affidavits from the other authors “disclaiming the invention claimed.” Appellant chose to appeal rather than comply with either requirement.

The Board’s Affirmance

While the board sustained the examiner’s rejection, it did so on the following ground:

The Chiorazzi et al. article, as pointed out by the examiner and as acknowledged by appellant, fully describes the presently claimed therapeutic immuno-suppressive agent and the method of preparing same. In view of the fact that the article was published some eight months prior to the effective filing date of the present application and since the authors of the article are legally another within the meaning of Section 102(a), we are satisfied that the examiner has clearly established a prima facie case of lack of novelty of the presently claimed therapeutic agent and method.
Appellant, who is a coauthor of the Chiorazzi article, has stated under oath that he is the sole inventor of the subject matter herein claimed and described in the article, and that the other authors, namely, Chiorazzi and Eshhar, are not coinventors but were simply students working under his direction and supervision. In appellant’s view, this declaration constitutes legally acceptable evidence and, in the absence of evidence to the contrary, is sufficient to establish that he is the sole inventor of the subject matter in issue.
However, we do not find this declaration, standing alone, sufficient to establish that Katz is the sole inventor and thus remove the Chiorazzi article as a reference against the presently claimed subject matter. Although appellant may be of the opinion that he is the sole inventor, such a view may not be shared by the coauthors of this article. Coauthors Chiorazzi and Eshhar may, in fact, be of the opinion that they are, at the very least, coinventors of the subject matter described in the article and claimed herein. Even though authorship may not conclusively establish inventor-ship, it is reasonable to infer that such a relationship exists. Appellant’s unsupported statement, even though under oath, does not convince us otherwise. In our view, disclaiming affidavits or declarations by the other authors are required in order to support appellant’s contention that he is the sole inventor of the subject matter described in the Chiorazzi article and claimed here. [Emphasis ours.]

The board adhered to its position on rehearing.

OPINION

Because the board did not specifically reverse the § 102(g) rejection, we treat it as having been affirmed. 37 CFR 1.196(a). Further, since appellant does not contend that the board’s reliance on § 102(a) is a new ground for rejection, we will also consider that section. 37 CFR 1.196(b). Appellant does suggest that the board apparently confused § 102(e) with § 102(a) since § 102(a) makes no reference to “another” in the context of authorship of a publication. However, we disagree that the board was “confused” in this respect for reasons which will become apparent and, accordingly, do not find it necessary to consider § 102(e) separately.

[454]*454 35 U.S.C. § 102(g)

Section 102(g) reads:

A person shall be entitled to a patent unless— ******

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Egenera, Inc. v. Cisco Sys., Inc.
348 F. Supp. 3d 99 (District of Columbia, 2018)
Allergan, Inc. v. Sandoz, Inc.
681 F. App'x 955 (Federal Circuit, 2017)
Allergan, Inc. v. Apotex Inc.
754 F.3d 952 (Federal Circuit, 2014)
Trebro Manufacturing, Inc. v. Firefly Equipment, LLC
748 F.3d 1159 (Federal Circuit, 2014)
Eli Lilly and Co. v. TEVA PHARMACEUTICALS USA
657 F. Supp. 2d 967 (S.D. Indiana, 2009)
In Re Omeprazole Patent Litigation
490 F. Supp. 2d 381 (S.D. New York, 2007)
AstraZeneca AB v. Mylan Laboratories Inc.
490 F. Supp. 2d 381 (S.D. New York, 2007)
Rhone-Poulenc Agro, S.A. v. Monsanto Co.
445 F. Supp. 2d 531 (M.D. North Carolina, 2006)
Invitrogen Corp. v. Biocrest Manufacturing, l.p.
424 F.3d 1374 (Federal Circuit, 2005)
Evans Medical Ltd. v. American Cyanamid Co.
11 F. Supp. 2d 338 (S.D. New York, 1998)
Odetics, Inc. v. Storage Technology Corp.
906 F. Supp. 324 (E.D. Virginia, 1995)
Specialty Manufacturing Co. v. School Bus Parts of Canada, Inc.
802 F. Supp. 1378 (W.D. North Carolina, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
687 F.2d 450, 215 U.S.P.Q. (BNA) 14, 1982 CCPA LEXIS 110, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-katz-ccpa-1982.